A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with RO7790121 compared with placebo in participants with moderately to severely active ulcerative colitis (UC).

开始日期2024-12-31

申办/合作机构

Hoffmann-La Roche, Inc.

ChiCTR2400093667 / Recruiting临床3期IIT

A phase III, multicenter, double-blind, placebo-controlled, treat-through study to assess the efficacy and safety of induction and maintenance therapy with RO7790121 in patients with moderately to severely active ulcerative colitis

开始日期2024-12-10

申办/合作机构-

NCT06589986 / Recruiting临床3期

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of RO7790121 compared with placebo in participants with moderately to severely active ulcerative colitis (UC).

开始日期2024-09-17

申办/合作机构

Hoffmann-La Roche, Inc.

[+1]

100 项与 Afimkibart 相关的临床结果

登录后查看更多信息

100 项与 Afimkibart 相关的转化医学

登录后查看更多信息

100 项与 Afimkibart 相关的专利（医药）

登录后查看更多信息

项与 Afimkibart 相关的文献（医药）

2021-11-01·Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association1区 · 医学

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study

1区 · 医学

Article

作者: Schoenbeck, Uwe ; Scherl, Ellen J ; Banfield, Christopher ; Li, Gang ; Vincent, Michael S ; Neelakantan, Srividya ; Ye, Zhan ; Chandra, Deepa E ; Peeva, Elena ; Rath, Natalie ; Hung, Kenneth E ; Klopocka, Maria ; Romatowski, Jacek ; Hassan-Zahraee, Mina ; Allegretti, Jessica R ; Lepsy, Christopher ; Danese, Silvio

BACKGROUND & AIMS:

An immune component of inflammatory bowel disease is up-regulated tumor necrosis factor-like ligand 1A (TL1A). Anti-TL1A antibodies such as PF-06480605, a fully human immunoglobulin G1 monoclonal antibody, may have therapeutic potential.

METHODS:

This Phase 2a, multicenter, single-arm, open-label study (TUSCANY) evaluated safety, tolerability, efficacy, pharmacokinetics, and immunogenicity in PF-06480605-treated participants with moderate to severe ulcerative colitis (UC). Participants received 500 mg intravenous PF-06480605 every 2 weeks, 7 doses total, with a 3-month follow-up period. Primary safety and efficacy endpoints were the incidence of adverse events (AEs) and week 14 endoscopic improvement (EI) (Mayo endoscopic subscore = 0 or 1), respectively. Secondary endpoints included total soluble TL1A (free/drug-bound) (sTL1A), incidence of anti-drug and neutralizing antibodies, PF-06480605 concentrations, and changes in fecal calprotectin and high-sensitivity C-reactive protein. Histology was assessed at week 14.

RESULTS:

The study enrolled 50 participants; 42 completed. Of 109 treatment-emergent AEs, 18 were treatment-related. The most common AEs were UC disease exacerbation and arthralgia (6 participants each). Four serious AEs, no deaths, and no malignancies were reported. Week 14 EI was observed in a statistically significant proportion of participants (38.2% [uniformly minimum-variance unbiased estimator, per protocol population]). Minimal histologic disease was observed after treatment (Robarts Histopathology Index ≤5: 33.3%; Geboes Index ≤3.2: 47.6%). sTL1A increase over time from baseline indicated sustained target engagement. Forty-one participants (82%) tested positive for anti-drug antibodies and 5 (10%) for neutralizing antibodies.

CONCLUSIONS:

PF-06480605 demonstrated an acceptable safety profile and statistically significant EI in participants with moderate to severe UC, warranting further study in a larger participant cohort. Tissue histopathology analyses support this conclusion.

TRIAL REGISTRATION NUMBER:

https://clinicaltrials.gov/NCT02840721.

2020-04-01·British journal of clinical pharmacology2区 · 医学

First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects

2区 · 医学

Article

作者: Lepsy, Christopher ; Goteti, Kosalaram ; Pawlak, Sylvester ; Rudin, Dan ; Hung, Kenneth E. ; Bhattacharya, Indranil ; Hassan‐Zahraee, Mina ; Brown, Lisa S. ; Banfield, Christopher ; Li, Gang

Aims:

Human genetic, tissue expression, proteomics, transcriptomics and nonclinical studies implicate tumour necrosis factor α‐like ligand 1A (TL1A) as a novel target in inflammatory bowel disease (IBD). PF‐06480605, a fully human immunoglobulin G1 monoclonal antibody, targets TL1A. This first‐in‐human, Phase 1, dose‐escalation study assessed safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of intravenous (IV) and subcutaneous (SC) PF‐06480605 in healthy subjects (NCT01989143).

Methods:

Ninety‐two subjects were randomized to single ascending doses (SAD), PF‐06480605 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg or 800 mg IV, or multiple ascending doses (MAD), PF‐06480605 3 × 500 mg IV, or 3 × 30 mg, 3 × 100 mg, or 3 × 300 mg SC every 2 weeks for three doses, or placebo. Safety, tolerability, pharmacokinetics, immunogenicity profiles and total TL1A, anti‐drug antibody (ADA) and neutralizing antibody (NAb) levels were assessed at pre‐determined times.

Results:

PF‐06480605 SAD up to 800 mg IV and MAD up to 300 mg ×3 SC and 500 mg ×3 IV were well tolerated. Overall, there were 45 and 44 treatment‐emergent adverse events in SAD and MAD cohorts, respectively, and no deaths or serious adverse events. PF‐06480605 exposure generally increased dose‐dependently. ADA and NAb levels did not impact safety, pharmacokinetics, or pharmacodynamics at higher doses. Target engagement was demonstrated through dose‐dependent differences in serum total soluble TL1A concentrations for PF‐06480605 vs placebo cohorts.

Conclusions:

PF‐06480605 was generally well tolerated, and binding of soluble TL1A was maintained throughout the dose interval, supporting further study of PF‐06480605 in patients with IBD and other inflammatory conditions.

The AAPS journal

Determination of Anti-drug Antibody Affinity in Clinical Study Samples Provides a Tool for Evaluation of Immune Response Maturation

Article

作者: Lepsy, Christopher ; Joyce, Alison ; You, Zhiping ; Shea, Christopher ; Gorovits, Boris

Abstract:

Characterization of clinical anti-drug antibody (ADA) responses to biotherapeutics can be important to understanding the consequences of immunogenicity. ADA are expected to be polyclonal, with composition and affinities that evolve over time. Measuring ADA binding affinity can be complicated by the polyclonal nature of response, residual drug in sample, and low ADA levels. We developed a novel workflow to determine the apparent ADA affinity (KD) against a monoclonal antibody biotherapeutic, PF-06480605. An affinity capture elution pre-treatment step was used to isolate ADA and remove residual drug interference from samples. Solution-phase equilibrium incubation was performed using drug and sample ADA as variable and fixed binding interactants, respectively. Unbound ADA concentration was measured using a Singulex Erenna ligand-binding assay (LBA) method. Apparent ADA KD values were calculated using a custom R Shiny algorithm. KD values determined for ADA positive samples showed good correlation with other immunogenicity parameters, including titers and neutralizing antibody (NAb) activity with a general increase in affinity over time, indicative of a maturing immune response. Time of onset of high affinity responses (KD < 100 pM) varied between patients, ranging from 16 to 24 weeks. Antibody responses appeared monophasic at earlier time points, trending towards a biphasic response with a variable transition time and general increase in proportion of high affinity ADA over time. Herein, we provide a novel, sensitive bioanalytical method to determine the KD of ADA in clinical samples. The observed decrease in ADA KD is consistent with evidence of a maturing immune response.Graphical Abstract

158

项与 Afimkibart 相关的新闻（医药）

2024-12-20

·医学新视点

近半数溃疡性结肠炎患者达缓解，效果维持超过3个月！创新疗法迎新突破

▎药明康德内容团队编辑赛诺菲（Sanofi）与梯瓦（Teva Pharmaceuticals）近日宣布，其共同开发的在研单抗duvakitug在临床2b期研究RELIEVE UCCD中达到了主要终点，接受duvakitug治疗的溃疡性结肠炎（UC）和克罗恩病（CD）患者在第14周时达成缓解，并展现出“best-in-class”疗法的潜力。根据新闻稿，这是首个评估肿瘤坏死因子样配体1A（TL1A）靶向单抗用于CD治疗的随机、安慰剂对照研究。详细结果预计将于2025年的科学会议上公布。赛诺菲与梯瓦计划在与监管机构讨论后启动相关3期临床试验。 UC与CD是炎症性肠病（IBD）的两种主要类型，属于胃肠道（GI）的慢性炎症性疾病，会导致腹痛、腹泻、直肠出血、疲劳和体重下降等症状。长期炎症可引发纤维化等并发症，纤维化是指肠壁瘢痕组织过度累积，可能导致肠道狭窄和阻塞，患者常需住院或手术治疗。目前，IBD尚无治愈方法，治疗目标是诱导和维持缓解，防止病情复发。 RELIEVE UCCD是一项为期14周的随机、双盲、剂量递增2b期研究，旨在评估duvakitug在中重度UC或CD成人患者中的疗效、安全性、药代动力学和耐受性。符合入组标准的患者被随机分配接受每两周皮下注射一次低、高剂量的duvakitug或安慰剂治疗。图片来源：123RF 分析结果显示： UC患者：接受duvakitug治疗的患者中，36.2%的低剂量组和47.8%高剂量组患者实现临床缓解，此数值在安慰剂组仅为20.45%。经安慰剂校正后，低剂量组和高剂量组患者在第14周的临床缓解率分别为15.7%（p=0.050）和27.4%（p=0.003），差异显著。 CD患者：26.1%低剂量组和47.8%高剂量组患者实现内镜缓解，此数值在安慰剂组为13.0%。经安慰剂校正后，低剂量组和高剂量组患者在第14周的内镜缓解率分别为13.0%（p=0.058）和34.8%（p<0.001），数据具显著差异。总体而言，各患者亚组间的治疗效果一致。此外，duvakitug在UC和CD患者中显示出良好的耐受性，未发现新的安全信号。治疗相关不良事件（AE）发生率在duvakitug和安慰剂组之间相当，均为50%。 ▲TL1A靶向疗法作用机制（图片来源：参考资料[3]） Duvakitug（曾用名TEV’574）是一款潜在“best-in-class”的人源IgG1-λ2单抗，靶向TL1A，又称肿瘤坏死因子（TNF）超家族成员15。TL1A通过与其受体DR3结合，可放大炎症反应并加速IBD相关纤维化的进展。靶向TL1A有望缓解IBD患者的过度免疫反应。赛诺菲与梯瓦在2023年达成合作，共同开发并商业化duvakitug，用于治疗UC和CD。赛诺菲主导3期临床开发项目。梯瓦负责产品在欧洲、以色列及指定国家与地区的商业化推广，赛诺菲则负责北美、日本、其他亚洲地区及全球其他市场的商业化。图片来源：123RF TL1A是近年IBD领域的新兴靶点，除了赛诺菲与梯瓦共同开发的duvakitug之外，罗氏（Roche）也在去年10月通过收购Telavant囊获其TL1A靶向抗体RVT-3101包括在美国和日本开发、生产和商业化的权利，目前该疗法已进入治疗UC患者的3期临床开发阶段。之前所公布的临床2b期试验结果显示，在经过生物标志物筛选的患者群体中，接受预期3期临床试验剂量RVT-3101治疗的患者的临床缓解率为40%，是安慰剂组（10%）的4倍（p=0.02）。这一群体的内镜改善率为56%，是安慰剂组（10%）的5.6倍（p=0.0005）。生物标志物阳性的患者群体约占总患者群体的60%。而默沙东（MSD）在去年6月通过收购Prometheus Biosciences所囊获的TL1A靶向单抗tulisokibart（MK-7240）目前也正在3期临床试验中接受评估其用以治疗UC与CD患者的潜力。此外，Spyre Therapeutics旗下的TL1A靶向单抗SPY002则已在这个月初完成1期试验的首位患者给药。根据该试验结果，Spyre预计在2025年启动SPY002用于治疗UC患者的2期试验。该疗法采用半衰期延长技术，有望实现每季度一次给药。今年6月，艾伯维（AbbVie）也与明济生物制药公司达成开发FG-M701的许可协议。这是一款靶向TL1A的全人源单克隆抗体，与第一代TL1A抗体相比，FG-M701通过独特的工程化改造，旨在为炎症性肠病治疗提供更高的疗效并减少给药频率，目前该疗法仍处于临床前开发阶段。相关阅读 JAMA子刊：结直肠癌肝转移一线治疗，“简化方案”有望成为首选 NEJM：2年无进展生存率72%！一线双重免疫疗法大幅改善结直肠癌疗效 CAR-T治疗转移性结直肠癌突破！JAMA子刊：73%患者获益，总生存期超26个月《柳叶刀》子刊：一次结直肠癌筛查，保护长达21年，发病/死亡风险降低1/4！参考资料： [1] Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease. Retrieved December 17, 2024 from https://www.sanofi.com/en/media-room/press-releases/2024/2024-12-17-12-30-00-2998154 [2] Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies. Retrieved December 17, 2024 from https://ir.spyre.com/2024-12-02-Spyre-Therapeutics-Announces-First-Participants-Dosed-in-Phase-1-Trials-of-Novel-Half-life-Extended-Anti-TL1A-Antibodies[3] Teva & Sanofi Transformative Anti-TL1A Collaboration. Retrieved October 4, 2023 from https://s24.q4cdn.com/720828402/files/doc_presentations/2023/10/TL1A-Teva-Presentation-2023-10-04-website.pdf 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

临床3期临床结果临床成功临床2期

2024-12-18

·医药魔方Info

赛诺菲15亿美元引进的TL1A单抗治疗炎症性肠病IIb期研究成功

12月17日，赛诺菲和梯瓦宣布IIb期RELIEVE UCCD研究达到了主要终点，该研究旨在评估duvakitug用于治疗中重度溃疡性结肠炎（UC）和克罗恩病（CD）患者的疗效、安全性、药代动力学和耐受性。结果显示，相比于安慰剂，duvakitug治疗组的患者获得了更高的临床缓解率，显示出best-in-class疗法的潜力。 Duvakitug是梯瓦公司研发的一款靶向肿瘤坏死因子（TNF）样配体1A（TL1A）的人源化IgG1-λ2单克隆抗体。TL1A通过与死亡受体3（DR3）结合并激活下游信号传导，然后调节效应细胞的增殖、激活、凋亡以及细胞因子、趋化因子的产生，参与先天和适应性免疫稳态的维护。研究发现，TL1A在自免疫疾病中异常表达，并参与类风湿性关节炎、银屑病和炎症性肠病（IBD）等自身免疫性疾病。TL1A因其独特的作用机制在炎症性反应等方面发挥重要作用。目前，TL1A已成为溃疡性结肠炎、克罗恩病等疾病的新靶点。 2023年10月，赛诺菲以5亿美元的首付款及最高达10亿美元的里程碑付款与梯瓦就该药的开发和商业化达成了合作。 RELIEVE UCCD研究是一项为期14周的随机、双盲IIb期研究。入组的受试者按1:1:1的比例随机分配接受每两周一次皮下注射的两种剂量的duvakitug或安慰剂治疗。主要疗效终点是UC队列中显示临床缓解的受试者人数（根据改良Mayo评分评估）或CD队列中显示内镜缓解的受试者人数（根据SES-CD内镜评分评估）。结果显示，在UC队列中，duvakitug低剂量组、高剂量组与安慰剂组分别有36.2%、47.8%、20.45%的患者实现了临床缓解，duvakitug两个剂量组经安慰剂校正后的临床缓解率分别为15.7%（p=0.050）和27.4%（p=0.003）。在CD队列中，三个治疗组的内镜缓解率分别为26.1%、47.8%、13.0%，duvakitug两个剂量组经安慰剂校正后的内镜缓解率分别为13.0%（p=0.058）和34.8%（p<0.001）。总体而言，duvakitug的治疗效果在各亚组中保持一致。详细结果预计将于2025年在科学论坛上公布。这是第一项也是唯一一项评估抗TL1A单克隆抗体治疗CD的随机、安慰剂对照研究。安全性方面，duvakitug在UC和CD患者中的耐受性普遍良好，未发现安全性信号。在UC和CD患者中，duvakitug组和安慰剂组的治疗相关不良事件（AE）总体发生率相似（均为50%）。在UC和CD患者中报告的所有AE发生率均低于5%。赛诺菲与梯瓦计划在与监管机构讨论后启动该药用于治疗IBD的III期临床研究。医药魔方数据库显示，目前全球共有7款TL1A单抗进入了临床研究阶段。赛诺菲与梯瓦的duvakitug全球研发进度排名第三，默沙东的tulisokibart和辉瑞/罗氏的PF-06480605已进入了III期临床研究阶段。 Copyright © 2024 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

临床结果临床3期临床2期引进/卖出临床成功

2024-12-17

·空之客

【药海听涛】炸裂但又没完全炸裂：TL1A单抗Duvakitug公布二期初步结果

在近两年以来的自免热潮中，TL1A无疑是最靓的仔，Merck以$10.8b收购Prometheus获得PRA-023、Roche以$7.25b从Roivant子公司收购RVT-3101的美日权利、Sanofi以$1.5b从Teva引进TEV-574的欧洲以外权利、Abbvie以$1.7b从明济生物引进FG-M701……MNC一顿风卷残云，将目前所有浮出水面的TL1A分子尽数收入囊中，仿佛攥住了制霸自免的希望。那么问题来了，TL1A真的值这么多钱么？随着前三个管线陆续披露临床数据，笔者的这一困惑好像也并没有完全被解开…… 12月17日Sanofi和Teva公布了合作开发的Duvakitug（TEV-574）的Phase 2b初步结果，这是一项代号RELIEVE UCCD的试验（NCT05499130），共入组了UC和CD患者各约120例，按1:1:1分配到高低剂量组和安慰剂组。 https://s24.q4cdn.com/720828402/files/doc_presentations/2024/12/Teva-Duva-Ph2-TLR_Dec17-2024_vF.pdf 乍一看14周诱导期的主要临床终点，感觉确实非常炸裂：UC部分，高剂量组的临床缓解率居然高达47.8%，断崖式领先其他两个TL1A分子以及目前几乎所有能看到的UC临床试验数据；CD部分，高剂量组的内镜响应率也高达47.8%，同样是目前CD临床数据中最亮眼的。于是联想起了TEV-574在临床前展现出BIC的活性和对DR3的高选择性（图中的TL1A#1/2大概率就是另外两个同靶点竞品，另将Spyre的对比作为旁证），仿佛一下子就与临床结果对得上了。然而我们不难发现，RELIEVE UC试验的安慰剂组表现好像有点过于出挑了，印象中UC的临床试验里很少有安慰剂效应这么高的，于是做了一下cross-trial对比，可以看出本次安慰剂组20%+的临床缓解率远远超出了历史上所有其他试验的安慰剂组水平，使得高剂量组TEV-574的48%绝对值黯然失色，经安慰剂修正后就成了泯然众人的27%，就算在现有三个TL1A分子中也只略占上风，甚至就还比不上Infliximab和Upadacitinib了。进一步地，TEV-574的短半衰期劣势十分明显，人体内t1/2约6-9天，而PRA-023和RVT-3101都在20天左右，所以前者Q2W、后两者Q4W；虽然TEV-574本次暂未披露具体剂量，但从一期临床的SAD和MAD剂量爬坡推测，有可能高低剂量组分别在1600mg和600mg Q2W，而PRA-023和RVT-3101的三期临床剂量则分别是500mg和450mg Q4W，TEV-574以明显更高的剂量和更短的给药间隔，却只获得略高一点的有效性边际优势，似乎就算不上是多么炸裂的表现了。看来看去，这次TEV-574的有效性数据好像十分炸裂但又没有完全炸裂，安慰剂效应的高企十分离奇，使得经安慰剂修正的临床缓解率并不算惊艳，相比另两个TL1A临床在研管线只有少许提高、也并不能碾压此前的anti-TNFα和JAKi。那么，为什么TL1A资产还会受到MNC如此重金追捧呢？附录：主要溃疡性结肠炎药物临床数据 1）诱导期 2）维持期

临床2期临床结果并购临床3期临床1期

100 项与 Afimkibart 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
活动性重度溃疡性结肠炎	临床3期	美国	F. Hoffmann-La Roche Ltd.	2024-11-07
活动性重度溃疡性结肠炎	临床3期	中国	F. Hoffmann-La Roche Ltd.	2024-11-07
活动性中度溃疡性结肠炎	临床3期	比利时	Hoffmann-La Roche, Inc.	2024-09-17
活动性中度溃疡性结肠炎	临床3期	葡萄牙	Hoffmann-La Roche, Inc.	2024-09-17
溃疡性结肠炎	临床3期	-	Roche Holding AG	2023-10-23
克罗恩病	临床2期	美国	Hoffmann-La Roche Ltd.	2023-07-24
克罗恩病	临床2期	比利时	Hoffmann-La Roche Ltd.	2023-07-24
克罗恩病	临床2期	保加利亚	Hoffmann-La Roche Ltd.	2023-07-24
克罗恩病	临床2期	加拿大	Hoffmann-La Roche Ltd.	2023-07-24
克罗恩病	临床2期	法国	Hoffmann-La Roche Ltd.	2023-07-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05107492 (CTgov)	临床1期	炎症性肠病	12	PF-06480605 (PF-06480605 450mg)	糧願淵獵夢遞憲繭壓製(鹹窪簾醖壓蓋鹹製餘齋) = 顧壓顧網糧餘網糧齋觸網構遞遞構積積蓋衊願 (艱觸製襯襯願廠繭齋鏇, 顧鏇網製窪願糧願憲顧 ~ 觸醖築膚網構範鏇鹽壓) 更多	-	2024-03-21
NCT05107492 (CTgov)	临床1期	炎症性肠病	12	placebo (Placebo)	齋蓋窪積襯範醖鬱鏇廠(築簾鹽餘艱淵顧糧廠遞) = 蓋壓蓋夢願鑰觸廠鑰鏇範艱壓蓋鬱憲鏇願簾壓 (築構願淵遞鏇餘艱膚簾, 鏇網餘鬱構淵膚齋選構 ~ 壓襯窪構衊繭憲積夢餘) 更多	-	2024-03-21
NCT04090411 (TUSCANY-2, Corporate Publications) 人工标引	临床2期	溃疡性结肠炎	-	RVT-3101	鹹窪淵選獵憲襯選構製(構膚鏇範醖廠構鏇製淵) = 餘膚衊構襯壓淵鹽製範獵醖鏇製鏇膚願構壓膚 (鑰鹹憲襯醖醖窪醖構淵 ) 更多	积极	2023-06-22
NCT02840721 (Phase 2a, CTgov)	临床2期	溃疡性结肠炎	50	PF-06480605	選製憲廠淵願膚餘獵遞(觸觸蓋構齋鏇鑰衊衊築) = 範顧壓壓獵壓齋製簾蓋鹹鬱淵鏇鹽觸艱製齋繭 (繭衊齋範簾簾壓憲襯餘, 鑰築築糧憲衊醖鏇淵網 ~ 鏇網製壓蓋構選顧廠廠) 更多	-	2019-06-19